| Quantity | 2 vials | Inquire | 1.5 million cells & Neural Plating-XF Medium | ~0.6x10^6 cells per 1ml of freezing medium (vial) | 20 nmol, 50 nmol, 100 nmol, 200 nmol |
| Description | Creative Biolabs offers a range of recombinant cell lines for Immunotherapy discovery and development. | Bifidobacterium are Gram-positive, heterofermentative, anaerobic bacteria with a distinctive bifid; i.e. Y shape after which they are named. They wre originally isolated from the faeces of breast-fed infants, members of the genus Bifidobacterium are commonly found in the GI tract of mammals. In Bifidobacterium are Gram-positive, heterofermentative, anaerobic bacteria with a distinctive bifid; i.e. Y shape after which they are named. They wre originally isolated from the faeces of breast-fed infants, members of the genus Bifidobacterium are commonly found in the GI tract of mammals. In humans, Bifidobacterium resides within the GI tract, from birth to old age. Disturbances in the microbiota are linked to an ever-growing number of immune-linked disease states including IBD, atopic allergy, arthritis, and obesity. Therefore, there is a significant interest in treating these diseases through microbial or "probiotic" supplementation of patients, including Bifidobacterium. Data from mouse models and clinical trials indicate that Bifidobacterium may have beneficial effects for treating and preventing immune-linked diseases, including gut-associated and systemic conditions. Bifidobacterium have been commercially exploited as probiotic agents due to their associated health benefits and GRAS.... Read More | Human iPSC-Derived Neural Stem Cells that have been genetically edited using CRISPR-Cas9 technology to introduce the G2019S mutation (GGC>AGC) in the LRRK2 gene. This line is homozygous for the G2019S mutation so both alleles contain the mutation.
The G2019S mutation in LRRK2 has been implicated in Human iPSC-Derived Neural Stem Cells that have been genetically edited using CRISPR-Cas9 technology to introduce the G2019S mutation (GGC>AGC) in the LRRK2 gene. This line is homozygous for the G2019S mutation so both alleles contain the mutation.
The G2019S mutation in LRRK2 has been implicated in autosomal-dominant familial Parkinson's disease with late onset (Fonzo et al., 2006, Thaler et al., 2009). The G2019S mutation increases the kinase activity of LRRK2 causing increased autophosphorylation and substrate phosphorylation that may affect neuronal cell health in Parkinson's disease patients (West et al., 2005).... Read More | iNeuMito™ is a mitochondrial calcium biosensor that responds in the fluorescence range of 605nm-625nm (excitation/emission: 610nm / 625nm) and has been integrated into iNeuRapid™, iNeu's proprietary immortalized human cell line. iNeuMito™-Rapid cells can be used as a control for iNeuMito™ is a mitochondrial calcium biosensor that responds in the fluorescence range of 605nm-625nm (excitation/emission: 610nm / 625nm) and has been integrated into iNeuRapid™, iNeu's proprietary immortalized human cell line. iNeuMito™-Rapid cells can be used as a control for all products containing iNeuMito™ biosensor.... Read More | The product SIRGT65419WQ is a type of small interfering RNA (siRNA) that targets CASTOR1 gene and regulates the expression of gene. The siRNA interferes with the expression of CASTOR1 gene with complementary nucleotide sequences by degrading mRNA after transcription, preventing translation. It has The product SIRGT65419WQ is a type of small interfering RNA (siRNA) that targets CASTOR1 gene and regulates the expression of gene. The siRNA interferes with the expression of CASTOR1 gene with complementary nucleotide sequences by degrading mRNA after transcription, preventing translation. It has potential applications in RNA interference (RNAi) and gene therapy development.... Read More |